Heart Transplantation: New Decade, New Perspectives DOI: 10.21470/1678-9741-2020-0601 transplant [4] . The PROCEED II trial showed ex-vivo perfusion using the Organ Care System® (TransMedics, Andover, Massachusetts, United States of America) to be equivalent to cold ischemic preservation and with no detrimental effect on short-term patient or graft outcomes [4] . In addition, ex-vivo machine perfusion in the context of DCD donation could allow reanimation of the heart and restoration to near physiological state prior to transplantation [5] .
Starting this year, the Mayo Clinic Transplant Center is launching a lung restoration center with the goal of increasing the availability for transplantation using ex-vivo lung perfusion. Optimized lungs will then be available to several transplant centers across the United States of America. With the improvement in ex-vivo perfusion technology, we envisage that a similar concept for heart preservation could be developed.
Allosensitization to human leukocyte antigens (HLA) remains one of the biggest impediments to safe heart transplantation. It reduces access to otherwise ABO-compatible donors thus increasing transplant waiting time [6] . Transplanting across a positive crossmatch is avoided due to the associated high risk of early graft rejection and poorer long-term outcomes from higher rates of coronary allograft vasculopathy [7] . However, in select, sensitized patients, de-sensitization protocols have been trialed to increase the chances of a negative crossmatch and improve transplant outcomes. Plasmapheresis and intravenous immunoglobulins have historically been the mainstay for desensitization treatments, aimed at removing currently circulating antibodies. More recently, monoclonal antibodies targeting specific cells of the immune system have been paired with these. Rituximab, which targets CD20 on B cells, aims to reduce the production of new antibodies. Similarly, Bortezumab, targeting plasma cells, inhibits antibody production but is more targeted towards anti-HLA I antibodies. Finally, Eculizumab targets the complement pathway and is currently being investigated for the treatment of sensitized heart transplant candidates in the DUET Cardiac Trial [8] .
Multi-organ transplantation involving the liver offers a unique opportunity to address pre-transplant sensitization. Liver allografts alone can decrease donor-specific antibodies (DSA) levels. Mayo Clinic reported the first experience of performing combined heartliver transplantation with implantation of the liver prior to the heart allograft. The aim was to protect the heart from antibody-mediated rejection (AMR). This technique successfully reduced DSA levels immediately after the liver transplant in all patients and resulted in normal cardiac allograft function, and only one case of AMR was recorded post-transplant [9] .
A final area of ongoing research in the context of heart transplantation focuses on detection of graft rejection. Traditionally, repeated endomyocardial biopsies are assessed for histological evidence of rejection. However, these procedures are associated with considerable morbidity over the long term such as catheter-related complications, tricuspid regurgitation, and renal insufficiency. In a select recipient population at low risk of rejection, gene expression profiling has reduced biopsy numbers without increased risk of serious adverse outcomes [10] . Alternatively, measurement of donorspecific cell-free deoxyribonucleic acid (DNA) has been proposed as a marker for cellular injury caused by rejection [11] . With a growing body of evidence to support less invasive methods of monitoring cardiac graft rejection, we hope to see a reduction in the need for invasive endomyocardial biopsies in the future.
While clearly conferring a survival benefit, heart transplantation is currently only available to a select cohort of patients. In addition, long-term morbidity and limited graft longevity renders transplantation a treatment rather than cure for heart failure. The ongoing developments promise to contribute to improve both organ availability and graft longevity over the coming decade.
